Gossamer bio to hold conference call with pah experts to discuss prosera phase 3 design and interim torrey ole results

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), announced today that it will hold a conference call with pah experts on tuesday, july 25th at 10 a.m. edt. gossamer's management team will be joined by world-renowned pah key opinion leaders, dr. ray benza, dr. ardi ghofrani, and dr. jim white to discuss the upcoming p.
GOSS Ratings Summary
GOSS Quant Ranking